For example, cabozantinib, a specific VEGFR2, MET, and AXL multitargets inhibitor, was investigated in a wide range of human cancers and it is currently approved for the treatment of metastatic patients with renal cell carcinomas [23]. This evidence concerns the gene MET and hereditary clear cell renal cell carcinoma.